OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Pinilla-Ibarz on Choosing Second-line BTK Inhibitors in CLL

October 5th 2022

Javier Pinilla-Ibarz, MD, PhD, discusses the factors that go into choosing the optimal second-line BTK inhibitors for patients with chronic lymphocytic leukemia.

Dr. Santa-Maria on Trastuzumab Deruxtecan in HER2-low TNBC

October 5th 2022

Cesar A. Santa-Maria, MD, discusses exploratory data seen with trastuzumab deruxtecan in patients with triple-negative breast cancer.

Dr. Johnson on the Evolution of Frontline Treatment in NSCLC

October 5th 2022

Melissa L. Johnson, MD, discusses the evolution of frontline treatment in non–small cell lung cancer.

Dr. Tkaczuk on the Utilization of Trastuzumab Deruxtecan in HER2+ Breast Cancer

October 5th 2022

Katherine Tkaczuk, MD, discusses the utilization of trastuzumab deruxtecan in HER2-positive breast cancer.

Dr. Strickler on the Importance of Targeted Therapies in HER2+ mCRC

October 5th 2022

John H. Strickler, MD, discusses the importance of investigating targeted therapies in HER2-positive metastatic colorectal cancer.

Dr. Ali on Ruxolitinib and Navitoclax Combination Therapy in Myelofibrosis

September 30th 2022

Haris Ali, MD, discusses the investigation of ruxolitinib and navitoclax combination therapy in myelofibrosis.

Dr. Wenham on the Importance of Clinical Trials in Ovarian Cancer

September 30th 2022

Robert Wenham, MD, MS, FACOG, FACS, discusses the importance of clinical trials in ovarian cancer.

Dr. Zhang on Multidisciplinary Approaches in Urothelial Cancer

September 30th 2022

Tian Zhang, MD, discusses the utilization of multidisciplinary approaches in urothelial cancers.

Dr. Kuykendall on Prognostication Factors in Myelofibrosis

September 29th 2022

Andrew Kuykendall, MD, discusses the evolution of prognostication factors in primary and secondary myelofibrosis.

Dr. Ornstein on Enfortumab Vedotin in Advanced Urothelial Carcinoma

September 29th 2022

Moshe Ornstein, MD, MA, discusses the use of the antibody-drug conjugate enfortumab vedotin in patients with advanced urothelial carcinoma that is refractory to chemotherapy and immunotherapy.

Dr. Arora on the Evolution of Treatment in Follicular Lymphoma

September 29th 2022

Madan L. Arora, MD, discusses the evolution of treatment in follicular lymphoma.

Dr. Chedid on Understanding Treatment Efficacy in Follicular Lymphoma

September 29th 2022

Solly Chedid, MD, discusses the elements of effective therapy in follicular lymphoma.

Dr. Patel on Factors to Consider When Treating Relapsed/Refractory Follicular Lymphoma

September 29th 2022

Krish Patel, MD, discusses the factors to consider when treating patients with relapsed and/or refractory follicular lymphoma.

Dr. Shah on the Significance of the Approval of Sodium Thiosulfate in Pediatric Solid Tumors

September 28th 2022

Nilay Shah, MD, discusses the significance of the approval of sodium thiosulfate for pediatric patients with cisplatin-treated pediatric solid tumors.

Dr. Schmid on the Use of Preoperative Radiation Therapy in Urothelial Carcinoma

September 28th 2022

Sebastian C. Schmid, MD, discusses the use of preoperative radiation therapy plus immunotherapy in urothelial carcinoma.

Dr. Ansell on the LOTIS-2 Trial of Loncastuximab Tesirine in R/R DLBCL

September 27th 2022

Stephen M. Ansell, MD, PhD, discusses the investigation of loncastuximab tesirine in the phase 2 LOTIS-2 trial in relapsed/refractory diffuse large B-cell lymphoma.

Dr. Paul on the Management of CRS and ICANS After CAR T-cell Therapy in Cancer Care

September 27th 2022

Barry Paul, MD, discusses the management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome following CAR T-cell therapy in cancer care.

Dr. Gerds on the VERIFY Trial Examining Rusfertide in Polycythemia Vera

September 27th 2022

Aaron T. Gerds, MD, MS, discusses the phase 3 VERIFY trial examining rusfertide in patients with polycythemia vera.

Dr. Popat on the Investigation of Lurbinectedin in Second-line SCLC

September 27th 2022

Sanjay Popat, MBBS, FRCP, PhD, discusses the investigation of lurbinectedin as a second-line treatment for patients with small cell lung cancer.

Dr. Orellana-Noia on the Treatment of High-Risk and Vulnerable Patient Populations with DLBCL

September 26th 2022

Victor M. Orellana-Noia, MD, discusses the treatment of high-risk and vulnerable patients with diffuse large B-cell lymphoma.